H.C. Wainwright & Co., 23rd Annual Investment Conference

ProMIS Executive Chairman, Eugene Williams, provides an update on the company with special focus on PMN310, ProMIS’ lead antibody for Alzheimer’s disease (AD), as well as an overview of the Company’s unique, proprietary technology platform and ProMIS’ expanding portfolio of antibody therapeutic candidates targeting in addition to AD, amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD) and beyond.